PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Inclusion Criteria: 1. Women aged 40-60 years; Men aged 30-50 years 2. Willing and able to provide informed consent and comply with study procedures 3. Smart phone user 4. Use of highly effective contraception by females with reproductive potential. 5. CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC\<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm) 6. Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab Exclusion Criteria: 1. Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD) 2. Current symptoms thought to be from CAD 3. PREVENT ASCVD 10-year risk ≥5% (if known) 4. Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known) 5. LDL-C ≥190mg/dL (most recent, if known) 6. HIV (if known) 7. Severe liver disease or untreated Hepatitis C infection (if known) 8. Pregnancy, lactation or intending to become pregnant during the study period of 2 years 9. eGFR \<45mL/min/1.73m2 (if known) 10. AST or ALT \>1.5x the upper limit of normal (if known) 11. BMI\>40kg/m2 or unable to have a CCTA scan for any reason 12. Allergy to iodinated intravenous contrast or other contraindication to CCTA 13. Current or previous use of lipid lowering therapy or colchicine 14. Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin. 15. Systemic cancer undergoing active treatment 16. PREVENT ASCVD 10-year risk ≥5% 17. eGFR \<45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available) 18. Hemoglobin A1c ≥6.5% per baseline labs 19. LDL-C ≥190mg/dL per baseline labs 20. Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis) 21. Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA) 22. Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.